Eli Lilly advances its obesity treatment pipeline with promising Phase 2b results for a novel drug combo that surpasses existing therapies in weight loss and metabolic improvements, setting the stage for future Phase 3 trials.
Eli Lilly has strengthened its lead in the fast-moving race to build more effective obesity treatments, after reporting late-stage data showing that a combination of its experimental amylin drug eloralintide and its approved obesity medicine Zepbound produced greater weight loss than tirzepatide alone in people with obesity and type 2 diabetes. The company said the Phase 2b study delivered weight loss of up to 23.3% over 48 weeks, alongside a marked reduction in blood glucose, a result that is especially notable in a population that typically responds less strongly to weight-loss drugs than people without diabetes.
According to Lilly, participants receiving the highest dose of the combination, dubbed EloraTZP, lost an average of 54.1 pounds and saw A1C fall by as much as 2.9%. The company said the findings were enough to justify advancing the programme into Phase 3 trials, which it plans to begin in the fourth quarter of 2026. In parallel, Lilly has also reported positive Phase 2 results for eloralintide on its own, saying the selective amylin receptor agonist produced meaningful weight loss in adults with obesity or overweight and was generally well tolerated over 48 weeks.
The data add another layer to the contest among drugmakers seeking to improve on today’s leading incretin-based therapies. Zepbound, also known as tirzepatide, is already a dual GIP and GLP-1 receptor agonist approved in the United States for chronic weight management, and Lilly has been positioning it as the foundation for next-generation combinations. BioCentury reported that the new results put Lilly ahead not only of Novo Nordisk’s CagriSema programme, but also of Lilly’s own triple-agonist candidate retatrutide, underscoring how quickly the company is iterating on its obesity pipeline.
For investors and doctors, the key question now is whether the stronger weight-loss numbers can translate into a durable treatment profile that remains tolerable for long-term use. Lilly has said Zepbound is intended to be used alongside diet and exercise, and the company’s own materials stress that it works by activating both GIP and GLP-1 receptors. The new data suggest that adding an amylin pathway may sharpen the effect further, though the real test will come in larger trials designed to confirm safety, tolerability and the extent to which the combination can outperform existing standards of care.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
